Changes in Hong Kong stocks | Cansino Biotech (06185) opened up nearly 13% and reached a strategic cooperation with Deputh Biotech for personalized mRNA treatment of oncology vaccines

The Zhitong Finance App learned that Cansino Biotech (06185) was nearly 13% higher. As of press release, it had risen 12.99% to HK$32, with a turnover of HK$11.116,800.

According to the news, Cansino Biotech announced that its subsidiary Cansino Shanghai and Deputh Biotech have officially signed the “Strategic Cooperation Framework Agreement for Joint Development of Personalized mRNA Tumor Vaccines”. The two sides will use their respective advantages in mRNA vaccine technology and the discovery and design of novel tumor antigens to jointly promote the development and commercialization of tumor vaccines for personalized mRNA therapy. The collaboration is global, focusing on the treatment of solid tumors and rare tumors of the digestive tract, covering early research and development, clinical transformation, registration and commercialization.

Notably, on August 19, Moderna and MSD announced that the phase III clinical trial of their jointly developed melanoma mRNA cancer vaccine had reached a major end. Lyon released a research report saying that since Moderna is conducting clinical research on the same platform for lung cancer, kidney cancer, and bladder cancer, this success is a platform-level valuation reassessment. The bank pointed out that Cansino Biotech's development route and antigen design are roughly similar to Moderna.